Clinical trials
catalyst calendar across sponsors →Studies where JANX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 15 tracked-famous managers (Point72 Asset Management, L.P., TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., Qube Research & Technologies Ltd, +10 more) · FINRA short interest 7.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate CancerNCT07545811Incidence of Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Biological: JANX014 | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer | 43 | May 2028 | ≤ 650 d | 2026-08-10 |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)NCT05519449Incidence of Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Biological: JANX007 · Drug: Darolutamide | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer | 272 | Jul 2027 | ≤ 345 d | 2026-08-13 |
| Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.NCT07291323Incidence, severity, and relatedness of TEAEs, treatment-emergent SAEs, and treatment-emergent AESIs.Open-label · Treatment | Early Phase 1 | Recruiting | Drug: JANX011 | Autoimmune | 60 | Oct 2026 | ≤ 72 d | 2026-04-23 |
| Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesNCT05783622Incidence of Dose Limiting Toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: JANX008 | Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer | 130 | 2026-07-31 | — | 2026-06-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19